Search clinical trials for: Trazenta

Total 50 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Real World Glycemic Effectiveness of Linagliptin

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

PMS of Trazenta on the Long-term Use as Add-on Therapy

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Medical Life Care Planners, LLC

Not yet recruiting

Suppression of Upper Lip Hair Growth Using Novel Hemp Extract

Hair Diseases | Hirsutism
Samsung Medical Center

Completed

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency (DA1229)

Renal Insufficiency | Albuminuria | Type2 Diabetes Mellitus

Korea, Republic of
University of Padova

Completed

Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes

Type 2 Diabetes | Chronic Renal Failure

Italy
Heart Care Foundation
Fondazione dell'Associazione Medici Diabetologi

Completed

Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry (DYDA2)

Diabetes Mellitus, Type 2 | Left Ventricular Systolic Dysfunction

Italy
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Diabetes Mellitus, Type 2

Korea, Republic of
Duramed Research

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Menopause

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Type2 Diabetes

Korea, Republic of
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
ikfe-CRO GmbH
MLM Medical Labs GmbH; Ikfe GmbH

Completed

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

Albuminuria | Arterial Hypertension

Germany
Medical University of Graz

Completed

Effects of Linagliptin on Endothelial Function

Coronary Artery Disease | Type 2 Diabetes

Austria
National Taiwan University Hospital

Unknown

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

Diabetes Mellitus | Osteoporosis
dr. DJ Mulder
Boehringer Ingelheim

Completed

Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (RELEASE)

Type 2 Diabetes Mellitus

Netherlands
Yanbing Li

Unknown

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Type 2 Diabetes Mellitus | Peritoneal Dialysis

China
Profil Institut für Stoffwechselforschung GmbH

Completed

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Type 2 Diabetes Mellitus

Germany
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
Boehringer Ingelheim

Terminated

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Diabetes Mellitus, Type 2

China
George Washington University
Boehringer Ingelheim

Completed

Linagliptin's Effect on CD34+ Stem Cells

Type 2 Diabetes | Impaired Renal Function

United States
University at Buffalo
Kaleida Health

Completed

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (1971)

Type 2 Diabetes

United States
RWTH Aachen University

Terminated

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (Diast Dysfkt)

Diabetes Mellitus Type 2 (T2DM) | Left Ventricular Diastolic Dysfunction

Germany
University of Miami

Withdrawn

Effects of DPP4 Inhibition on COVID-19

Coronavirus Infection | Type 2 Diabetes

United States
Postgraduate Institute of Medical Education and...

Unknown

Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Insulin Sensitivity/Resistance

India
Boehringer Ingelheim

Completed

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Diabetes Mellitus, Type 2

United States, Canada, Thailand, Korea, Republic of, United Kingdom, China, Germany, Israel, Mexico, Argentina, Brazil, Colombia, Puerto Rico, Russian Federation
Dong Wha Pharmaceutical Co. Ltd.

Completed

the Pharmacokinetic Profiles of Linagliptin With DW1029M (PLID)

Healthy

Korea, Republic of
Mayo Clinic
University of California, San Francisco; Ethicon, Inc.

Completed

Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction

Breast Cancer | Nonmalignant Breast Conditions

United States
Amsterdam UMC, location VUmc

Completed

Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS)

Type 2 Diabetes

Netherlands
Rabin Medical Center

Unknown

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

DM2
University of Nevada, Reno
Augusta University

Completed

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Schizophrenia

United States
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes (4T)

Insulin Resistance | Prediabetic State

Mexico
RenJi Hospital

Terminated

Efficacy and Safety of Empagliflozin in NODAT

Kidney Transplant; Complications | New Onset Diabetes After Transplant

China
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
Mackay Memorial Hospital

Unknown

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Type2 Diabetes

Taiwan
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
RWTH Aachen University

Terminated

Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus (Lina-Plaque)

Diabetes Mellitus Type 2 (T2DM) | Vascular Inflammation | Plaque Morphology

Germany, Netherlands
University Hospital, Gentofte, Copenhagen
Eli Lilly and Company

Completed

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Type 2 Diabetes

Denmark
Institut für Pharmakologie und Präventive Medizin
University of Erlangen-Nürnberg Medical School

Completed

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes (ELMI)

Diabetes Mellitus Type 2

Germany
Beth Israel Deaconess Medical Center

Completed

The Effect of Linagliptin on Mitochondrial and Endothelial Function

Type II Diabetes Mellitus

United States
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Erasme University Hospital

Terminated

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Type 2 Diabetes | Pancreas | Incretinomimetics

Belgium
Seoul National University Hospital
Daewoong Pharmaceutical Co. LTD.

Completed

The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim

Completed

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Diabetes Mellitus, Type 2

Bulgaria, Czechia, Hungary, Poland, Russian Federation
M.H.H. Kramer

Active, not recruiting

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES (RACELINES)

Type2 Diabetes

Netherlands
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States

Search clinical trials for: Trazenta

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations